| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 12/11/2003 | WO2003102180A1 NOVEL PEPTIDES HAVING cAMP PRODUCING ACTIVITY |
| 12/11/2003 | WO2003102177A1 METHOD OF SCREENING COMPOUND AFFECTING AMYLOID β PRODUCTION |
| 12/11/2003 | WO2003102168A1 Attenuated listeria spp. and methods for using the same |
| 12/11/2003 | WO2003102138A2 Elongase genes and uses thereof |
| 12/11/2003 | WO2003101997A1 Process of preparation of olanzapine form i |
| 12/11/2003 | WO2003101990A1 1-(aminoalkyl)-3-sulfonylazaindoles as 5-hydroxytryptamine-6 ligands |
| 12/11/2003 | WO2003101989A1 Inhibitors of jak and cdk2 protein kinases |
| 12/11/2003 | WO2003101987A1 3-substituted quinuclidines and their use |
| 12/11/2003 | WO2003101985A1 2-oxo-1,3,4-trihydroquinazolinyl derivatives for the treatment of cell proliferation-related disorders |
| 12/11/2003 | WO2003101984A1 Substituted thiophenes, method for the production thereof, their use as a medicament or diagnostic reagent, and a medicament containing the same |
| 12/11/2003 | WO2003101981A1 Novel substituted indoles |
| 12/11/2003 | WO2003101980A1 1,3,5-triazine derivatives as ligands for human adenosine-a3 receptors |
| 12/11/2003 | WO2003101978A1 Phenyl-thiophene type vitamin d receptor modulators |
| 12/11/2003 | WO2003101974A1 Aralkyl-alcohol peiperazine derivatives and their uses as antidepressant |
| 12/11/2003 | WO2003101970A1 Imidazolium cxcr3 inhibitors |
| 12/11/2003 | WO2003101968A1 Pyrazole compound and medicinal composition containing the same |
| 12/11/2003 | WO2003101964A1 Piperidine derivative, process for producing the same, and use |
| 12/11/2003 | WO2003101962A1 1-(aminoalkyl)-3-sulfonylindole and -indazole derivatives as 5-hydroxytryptamine-6 ligands |
| 12/11/2003 | WO2003101959A1 Pyrrole compounds for the treatment of prostaglandin mediated diseases |
| 12/11/2003 | WO2003101958A2 Flourinated cyclic amides as dipeptidyl peptidase iv inhibitors |
| 12/11/2003 | WO2003101957A1 New salts |
| 12/11/2003 | WO2003101950A2 Methods for enhancing motor performance and/or endurance |
| 12/11/2003 | WO2003101932A2 Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
| 12/11/2003 | WO2003101927A1 Compounds, compositions and methods for the treatment of amyloid diseases and synucleinopathies such as alzheimer's disease, type 2 diabetes, and parkinson's disease |
| 12/11/2003 | WO2003101492A2 Combination of atypical antipsychotic and serotonin reuptake inhibitor for the treatment of chronic pain |
| 12/11/2003 | WO2003101490A1 Drug composition containing calcium channel antagonist |
| 12/11/2003 | WO2003101487A1 Use of inhibitors of phospholipase a2 for the treatment, prevention or diagnosis of neural inflammatory or demyelinating disease |
| 12/11/2003 | WO2003101481A1 Treatment of neurodegenerative diseases using proteasome modulators |
| 12/11/2003 | WO2003101466A1 Rubrofusarin glycoside-containing composition |
| 12/11/2003 | WO2003101458A1 A combination of an nmda-antagonist and acetylcholine esterase inhibitors for the treatment of alzheimer's disease |
| 12/11/2003 | WO2003101456A1 Use of compounds that stimulate cgmp |
| 12/11/2003 | WO2003101455A2 Pharmaceutically active compounds having a tricyclic pyrazolotriazolopyrimidine ring structure and methods of use |
| 12/11/2003 | WO2003101454A1 A buffered, liquid nicotine composition for pulmonary administration |
| 12/11/2003 | WO2003101453A1 Triple monoamine reuptake inhibitors for the treatment of chronic pain |
| 12/11/2003 | WO2003101450A1 N- ((3-oxo2, 3-dihydro-1h-isoindol-1-yl) acetyl) guanidine derivatives as nhe-1 inhibitors for the treatment of infarction and angina pectoris |
| 12/11/2003 | WO2003101443A1 The use of milnacipran for the treatment of tension-type headache |
| 12/11/2003 | WO2003101441A1 Monotherapy for the treatment of amyotrophic lateral sclerosis with cyclooxygenase-2 (cox 2) inhibitor(s) |
| 12/11/2003 | WO2003101432A1 Combination immediate release controlled release levodopa/carbidopa dosage forms |
| 12/11/2003 | WO2003101430A1 Pharmaceutical composition containing oxcarbazepine and having a controlled active substance release |
| 12/11/2003 | WO2003101424A1 Modified release pharmaceutical formulation |
| 12/11/2003 | WO2003101402A2 Methods of treating cognitive dysfunction by modulating brain energy metabolism |
| 12/11/2003 | WO2003101392A2 Novel conazole crystalline forms and related processes, pharmaceutical compositions and methods |
| 12/11/2003 | WO2003101384A2 Dosage forms and compositions for osmotic delivery of variable dosages of oxycodone |
| 12/11/2003 | WO2003101380A2 Amyotrophic lateral sclerosis treatment with cyclooxygenase-2 inhibitors |
| 12/11/2003 | WO2003101374A2 Use of new etonogestrel esters |
| 12/11/2003 | WO2003101358A1 Implantable polymeric device for sustained release of buprenorphine |
| 12/11/2003 | WO2003101217A1 Ketoprofen-supplemented animal feed and use thereof in the simultaneous treatment of a group of animals for processes which are accompanied by fever, inflammation and/or pain |
| 12/11/2003 | WO2003101188A1 Chronic stress-related disease model animal and method of constructing the same |
| 12/11/2003 | WO2003092790A3 Methods for increasing the therapeutic response to electroconvulsive therapy ('ect') |
| 12/11/2003 | WO2003087090A3 Novel heteroaryl alkylamide derivatives useful as bradykinin receptor modulators |
| 12/11/2003 | WO2003084984A8 Heterocyclic amides with alpha-4 integrin antagonist activity |
| 12/11/2003 | WO2003080566A3 Hif hydroxylase inhibitors |
| 12/11/2003 | WO2003057666A3 Inhibitors of dipeptidyl peptidase iv |
| 12/11/2003 | WO2003048117A3 Propanolaminomethyltetralines, their preparation and pharmaceutical composition comprising same |
| 12/11/2003 | WO2003032912A3 Treatment of cns disorders using cns target modulators |
| 12/11/2003 | WO2003027090A3 Bicyclic heterocycles as rxr ligands |
| 12/11/2003 | WO2003026579A3 Combination therapies for immune mediated diseases |
| 12/11/2003 | WO2003026564A3 Pharmaceutical compositions for the treatment of urinary disorders |
| 12/11/2003 | WO2003024395A3 Linked biaryl compounds |
| 12/11/2003 | WO2003022216A3 Biaryl substituted purine derivatives as potent antiproliferative agents |
| 12/11/2003 | WO2003001882A3 Putative neurotransmitter receptor (pnr) disruptions, compositions and methods relating thereto |
| 12/11/2003 | WO2002094176A3 Use of compounds with combined nep/mp-inhibitory activity on the preparation of medicaments |
| 12/11/2003 | WO2002091858A8 Anxiolytic marcgraviaceae compositions containing betulinic acid, betulinic acid derivatives, and methods |
| 12/11/2003 | WO2002088114A3 Heteroaryl ofefinic azacyclic and heteroaryl acetylenic azacyclic compounds for the treatment of cns disorders |
| 12/11/2003 | WO2002087465A3 Compositions and methods of double-targeting virus infections and cancer cells |
| 12/11/2003 | WO2002083841A3 Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
| 12/11/2003 | WO2002083071A3 Heterocyclic analgesic compounds and methods of use thereof |
| 12/11/2003 | WO2002067986A3 Symbiotic regenerative agent |
| 12/11/2003 | WO2002065136A3 Yeast screens for agents affecting protein folding |
| 12/11/2003 | WO2002060928A3 Medane genes and proteins |
| 12/11/2003 | WO2002041884A8 Inhibitors of abc drug transporters at the blood-brain barrier |
| 12/11/2003 | US20030229907 Transgenic non-human mammals with progressive neurologic disease |
| 12/11/2003 | US20030229217 Comprises gamma-amino butyric acid (GABA) receptor subunits for treatment of obesity, vision defects, high blood pressure, depression and sexual disorders |
| 12/11/2003 | US20030229209 Comprises mitogen-activated protein (MAP) kinase polypeptide for treating muscular, diabetic and nervous system disorders |
| 12/11/2003 | US20030229208 Humanized immunoglobulins |
| 12/11/2003 | US20030229199 Modulator comprising cyclic peptide for use in treatment of cancer, gastrointestinal, inflammatory and nervous system disordrers |
| 12/11/2003 | US20030229148 2-aminotetralines, a process for their preparation, and pharmaceutical compositions, for the prevention and therapeutic treatment of inflammatory and/or autoimmune pathologies |
| 12/11/2003 | US20030229145 Analgesics; amino acid drug |
| 12/11/2003 | US20030229144 Anti-epileptogenic agents |
| 12/11/2003 | US20030229138 Aza hydroxylated ethyl amine compounds utility |
| 12/11/2003 | US20030229134 Methods for stimulating nervous system regeneration and repair by inhibiting phosphodiesterase type 4 |
| 12/11/2003 | US20030229130 Imidazolinylmethyl aralkylsulfonamides |
| 12/11/2003 | US20030229127 Heterocyclic sulfonamide inhibitors of beta amyloid production |
| 12/11/2003 | US20030229122 Use of methylphenidate compounds to enhance memory |
| 12/11/2003 | US20030229116 Enamine derivatives |
| 12/11/2003 | US20030229110 Cell signal transduction |
| 12/11/2003 | US20030229104 Substituted 3,4-dihydropyrido[1,2-a]pyrimidines |
| 12/11/2003 | US20030229102 Sulfonamide derivatives |
| 12/11/2003 | US20030229096 Substituted imidazol-pyridazine derivatives |
| 12/11/2003 | US20030229092 Antidiabetic agents; antiinflammatory agents; analgesics; antiallergens |
| 12/11/2003 | US20030229091 Heteroaromatic substituted cyclopropane as corticotropin releasing hormone ligands |
| 12/11/2003 | US20030229088 Novel methods and compositions for alleviating pain |
| 12/11/2003 | US20030229086 Central nervous system disorders; side effect reduction |
| 12/11/2003 | US20030229084 Osteoporosis; antiarthritic agents |
| 12/11/2003 | US20030229083 Compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them |
| 12/11/2003 | US20030229081 Antiinflammatory agents, antiischemic agents, malaria, Crohn's disease, skin disorders |
| 12/11/2003 | US20030229074 Metabolism; eating disorders; sexual disorders |
| 12/11/2003 | US20030229069 1-Sulfonyl-4-aminoalkoxy indole derivatives and uses thereof |
| 12/11/2003 | US20030229068 Controlling apoptosis, cell proliferation; strokes; anticancer agents; central nervous system disorders |
| 12/11/2003 | US20030229054 Novel amines as pharmaceutical agents |